Combination treatment for advanced colorectal cancer with specific gene changes
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three medicines (gossypol acetate, FOLFIRI chemotherapy, and bevacizumab) for people with advanced colorectal cancer that has a specific genetic change. The goal is to see if this combination helps shrink or slow the cancer better than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman aged 18 or older.
- You must have colorectal cancer that has spread to other parts of the body (metastatic) and cannot be removed with surgery.
- You must have already received one line of treatment with a chemotherapy drug called oxaliplatin (like FOLFOX).
- Your tumor must have a specific genetic change (TP53 mutation) and a protein marker (LRPPRC positive).
- Your overall health should be good enough that you can still care for yourself (ECOG 0-2).
- You should not have had prior treatment with irinotecan, and your liver, kidney, and bone marrow function must be within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (liposomal irinotecan, 5-FU/LV, and bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this treatment is safe and effective in shrinking tumors and improving outcomes.
This trial tests a combination of chemotherapy (5-FU/LV, irinotecan, and temozolomide) plus bevacizumab in metastatic colon or rectal cancer. It focuses on tumors with an “MGMT silenced” pattern (MGMT gene turned off), which may make some cancers more responsive to these medicines.
This trial tests a new drug combined with standard chemotherapy and another medication for people with advanced colorectal cancer that has a specific genetic change (RAS mutation). It aims to see if the combination can help control the cancer better.
This study tests a combination of three drugs (doxorubicin liposome, capecitabine, oxaliplatin) plus a targeted therapy called bevacizumab for people with advanced colorectal cancer that has a specific genetic change (SMAD4 R361H/C). The goal is to see if this combination can shrink tumors and slow cancer growth.
This study tests a new combination treatment for advanced colorectal cancer that has stopped responding to standard treatments or is newly diagnosed. It aims to see if the combination can shrink tumors or slow their growth.
This trial tests a combination of two targeted drugs (sintilimab and bevacizumab) with chemotherapy for people whose colorectal cancer has not spread to the liver. It aims to see if this combo helps control the cancer better after the first treatment stops working.
Hear when a new Patients With Metastatic Colorectal Cancer Who Were TP53-mutant and LRPPRC-positive and Had Previously Failed Prior First-line Treatment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.